Guardat en:
| Autors principals: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Recurso digital |
| Idioma: | anglès |
| Publicat: |
Zenodo
2026
|
| Matèries: | |
| Accés en línia: | https://doi.org/10.1111/ene.70493 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Taula de continguts:
- BACKGROUND: Recent epidemiological studies on the general population reveal that up to 1.3% have oligo/asymptomatic hyperCKemia. OBJECTIVE: This guideline aims to provide updated, evidence-based recommendations on investigating persons older than 18 years. METHODS: The guideline followed EAN standard operating procedures and was developed according to the GRADE methodology. Fourteen neuromuscular experts from the EAN neuromuscular group were joined by a methodologist and a patient representative. There are two types of recommendations: evidence-based recommendations, based on published studies, and consensus statements if the quality of evidence is poor. RESULTS: We recommend that: (1) Persistent oligo/asymptomatic hyperCKemia with a CK > 1.5 ULN be investigated (Consensus statement); (2) Neurogenic and non-neuromuscular causes of hyperCKemia be excluded (Expert opinion); (3) A Dried Blood Spot (DBS) be done (Strong recommendation); (4) A NCS/EMG to identify whether there is a myopathy or neuropathy be performed (Weak recommendation); (5) A resting lactate and fasting acyl-carnitine assays, if a metabolic myopathy is suspected, be done (Consensus statement); (6) A skeletal muscle MRI be performed to guide/interpret genetic testing (Strong recommendation); (7) NGS is recommended over sequential gene testing (Consensus statement); (8) NGS is recommended over muscle biopsy (Strong recommendation); (9) A muscle biopsy may be offered, if genetic testing is uninformative and one or more applies: a genetic variant of unknown significance (VUS), suspected metabolic myopathy, suspected inflammatory myopathy, abnormal muscle MRI, a CK = 3 ULN, a family history of muscle disease or age, less than 25 years (Expert opinion). CONCLUSIONS: An evidence-based guideline is suggested for when and how to investigate adults with oligo/asymptomatic hyperCKemia. © 2026 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.